City

Boston (1)

Houston (1)

Nassau Bay (1)

Sugar Land (1)

The Woodlands (1)

Condition

Grade 3 Endometrial Endometrioid Adenocarcinoma (2)

Cytoreductive Surgery (1)

Endometrial Clear Cell Adenocarcinoma (1)

Endometrial Mixed Adenocarcinoma (1)

Endometrial Mixed Cell Adenocarcinoma (1)

Endometrial Serous Adenocarcinoma (1)

Endometrial Undifferentiated Carcinoma (1)

High Grade Serous Carcinoma (1)

Malignant Mixed Mesodermal (Mullerian) Tumor (1)

Overall Status

Active, not recruiting (1)

Not yet recruiting (1)

Phase

n/a (2)

Sponsor

M.D. Anderson Cancer Center (1)

Massachusetts General Hospital (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

computed tomography (1)

indocyanine green solution (1)

laboratory biomarker analysis (1)

lymph node mapping (1)

lymphadenectomy (1)

pet/mri with radiotracer ([18f]- fluorodeoxyglucose) and a gadolinium-based contrast agent (1)

positron emission tomography (1)

Study Documents

Intervention Type

combination product (1)

drug (1)

other (1)

procedure (1)

Funder Type

Other (2)

Study Type

Interventional (2)

grade 3 endometrial endometrioid adenocarcinoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in United

Active, not recruiting

Endometrial Clear Cell Adenocarcinoma
+4 more

Computed Tomography
+5 more

Houston, Texas
+6 more

Dec 5, 2022

Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma, High Grade Serous Carcinoma Trial in Boston (PET/MRI

Not yet recruiting

Cytoreductive Surgery
+4 more

PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent

Boston, Massachusetts

Massachusetts General Hospital

May 21, 2022